Luxembourg – tranScrip, a renowned contract drug development organization, is thrilled to announce the appointment of Marianne Lambertson as the new Chief Commercial Officer. Lambertson brings a wealth of experience and a proven track record of success in the pharmaceutical and healthcare sectors to her new role at tranScrip.
Prior to joining tranScrip, Lambertson honed her skills at Biopharm Consulting LLC, where she served as Principal and Founder from 2010 to 2024. During her tenure, she collaborated extensively with various entities, including biotech firms, startups, multinational companies, and healthcare-focused investment banks, to bolster their strategic commercial capabilities and fundraising efforts.
From 2019 to 2021, Lambertson was the Chief Development Officer at Grace Place for Children and Families in Naples, Florida. Here, she successfully led initiatives that significantly enhanced the organization’s fundraising and strategic marketing efforts.
Her role prior to Grace Place was as Vice President of Corporate Communications and Investor Relations at Verastem Oncology, based in the Greater Boston Area, from 2017 to 2019. Lambertson’s leadership was pivotal in redefining the company’s communication strategies and enhancing stakeholder relations.
About tranScrip:
tranScrip is a leading service provider in the pharmaceutical and biotech sectors, specializing in the development and lifecycle management of medicines. Based in Luxembourg, tranScrip supports a global clientele with innovative solutions from translational medicine to registration and beyond. The company’s extensive expertise spans clinical, regulatory, drug safety, and commercial disciplines, ensuring comprehensive support for drug candidates from early development stages through to market launch. Over the past decade, tranScrip has been instrumental in advancing numerous therapeutic innovations, supporting over 250 clients in bringing critical health solutions to market.
Also Read: Talent Management and Coaching: Revolutionizing the Workplace in 2024
